IMV Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Andrew Hall

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage	47.1%
CEO tenure	2.8yrs
CEO ownership	n/a
Management average tenure	2.8yrs
Board average tenure	2.7yrs

Recent management updates

Recent updates

IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5%

Dec 03

IMV reports Q3 results

Nov 12

CEO Compensation Analysis

How has Andrew Hall's remuneration changed compared to IMV's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2022	US$1m	US$480k	-US$38m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$43m
Mar 31 2022	n/a	n/a	-US$40m
Dec 31 2021	US$884k	US$381k	-US$37m
Sep 30 2021	n/a	n/a	-US$32m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$26m
Dec 31 2020	US$511k	US$40k	-US$26m

Compensation vs Market: Andrew's total compensation ($USD1.02M) is above average for companies of similar size in the US market ($USD663.90K).

Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.

CEO

Andrew Hall

2.8yrs

Tenure

US$1,020,100

Compensation

Mr. Andrew Hall, B. Med. Sci., M.Sc. has been Chief Executive Officer of IMV Inc. since December 2021. Mr. Hall served as an Interim Chief Executive Officer at IMV Inc. since August 4, 2021 until December...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Andrew Hall	CEO & Director	2.8yrs	US$1.02m	no data
Brittany Davison	Chief Accounting Officer	1.7yrs	US$388.50k	0.013% $ 0.001
Delphine Davan	Senior Director of Communications & Investor Relations	no data	no data	no data
Stephan Fiset	Vice President of Clinical Research	6.9yrs	no data	no data

2.8yrs

Average Tenure

Experienced Management: IMVI.Q's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Andrew Hall	CEO & Director	2.3yrs	US$1.02m	no data
Brittany Davison	Chief Accounting Officer	1.2yrs	US$388.50k	0.013% $ 0.001
Michael Bailey	Independent Chairman	3.5yrs	US$154.42k	0% $ 0
Nina Bhardwaj	Member of Scientific & Clinical Advisory Committee	no data	no data	no data
Jose Iglesias	Member of Scientific & Clinical Advisory Committee	no data	no data	no data
Shabnam Kazmi	Independent Director	1.3yrs	no data	no data
Markus Warmuth	Independent Director	5.5yrs	US$118.88k	0% $ 0
Kyle Kuvalanka	Independent Director	3.1yrs	US$113.88k	0% $ 0
Michael Kalos	Independent Director and Member of Scientific & Clinical Advisory Committee	3yrs	US$108.25k	0% $ 0
Saman Maleki	Independent Director	1.7yrs	US$135.01k	0.0044% $ 0.0005

2.7yrs

Average Tenure

55yo

Average Age

Experienced Board: IMVI.Q's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

IMV Management

Management criteria checks 1/4

Key information

Recent management updates

High number of new directors

IMV Inc. Announces Board Changes

IMV Inc. Announces Board Changes

High number of new directors

High number of new directors

IMV Inc. Announces Andrew Sheldon Not Stand for Re-Election to the Board

Recent updates

IMV Inc. Files Form 15

Nasdaq to Delist the Common Shares of IMV

IMV Inc.(OTCPK:IMVI.Q) dropped from NASDAQ Composite Index

IMV Receives Nasdaq Delisting Notice

IMV Inc. Presents Positive Initial Results from the MVP-S Phase 2B Vitalize Trial

High number of new directors

IMV Inc. Announces Board Changes

IMV Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

IMV Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

Imv Inc. Announces Initial Data from the Ongoing Phase 2B Vitalize Trial in Patients with R/R Dlbcl

IMV Inc. to Report Q3, 2022 Results on Nov 11, 2022

IMV Inc. Announces Board Changes

IMV to cut ~33% workforce amid reorganization

High number of new directors

IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

IMV receives Nasdaq non-compliance letter

High number of new directors

IMV Inc. Announces Andrew Sheldon Not Stand for Re-Election to the Board

IMV Inc. announced that it has received $25 million in funding from Horizon Technology Finance Management, LLC

IMV Inc. Appoints Michael P. Bailey as Chairman of the Board

IMV Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL

IMV Inc Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts

IMV Inc. announces new translational data implicating B cells in the clinical benefit induced by MVP-S treatment in ovarian cancer patients

IMV Inc. Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer

IMV Inc. Announces Final Topline Results of the Decide1 Clinical Trial

CEO & Director Frederic Ors has left the company

High number of new directors

CEO & Director recently bought US$147k worth of stock

Chief Medical Officer Joanne Schindler has left the company

IMV names Jeremy Graff as chief scientific officer

Imv Inc. Leads Immunotherapy to Be Investigated in Breast Cancer

Independent Director has left the company

Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019)

IMV Inc. to Report Q4, 2020 Results on Mar 17, 2021

New 90-day high: US$4.36

IMV Reports Update on COVID-19 Vaccine Program

IMV's vaccine candidate potentially effective against COVID-19, shares up 16%

New 90-day low: US$3.13

Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting

IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer

IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5%

Revenue and earnings beat expectations

IMV reports Q3 results

IMV Inc. Appoints Andrew Hall as Chief Business Officer

IMV's T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck's Keytruda® in PD-L1 Positive Patients with r/r DLBCL

IMV Inc. Provides Updated Clinical Data from Phase 2 SPiReL Study Evaluating its T Cell Therapy in Combination with Merck’s Keytruda in Patients with R/R DLBCL

New 90-day low: US$3.15

IMV Inc Announces That Biomarkers Associated with Clinical Response in Patients with R/R DLBCL Treated with DPX-Survivac

New 90-day low: US$3.85

IMV Inc. Provides Updates on Its Vaccine Candidate, DPX-COVID-19, for the Prevention of Infection Caused by the Novel Coronavirus SARS-COV-2

Earnings released

IMV Inc. to Report Q2, 2020 Results on Aug 12, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age